Sage Therapeutics Inc (SAGE)

[Biobonic]

Post-hoc analysis revealed that in the MOUNTAIN Study, approximately 9% of patients in the SAGE-217 30 mg group had no measurable drug concentration, consistent with non-compliance in taking SAGE-217

In the 30mg group, 192 received the medication at the onset of the trial.

9% would approximate: 17 participants.

The trial had 28 participants withdraw by day 42. (14%) a significant number, especially since there was a good measure of efficacy.